| Take heed to this text |
Last month, EDAP TMS SA and Avenda Health announced a joint initiative to offer personalized prostate cancer treatment leveraging Avenda’s cutting-edge Unfold AI technology. Their stated goal is to bring the Focal One robotic platform to market, leveraging artificial intelligence to facilitate high-intensity focused ultrasound (HIFU) treatments.
Avenda Health’s Unfold AI is a multimodal AI decision-support platform that has received clearance from the U.S. Meals and Drug Administration (FDA). According to the announcement, the technology is likely to create highly detailed, three-dimensional patient-specific cancer maps, which can reveal the scope of tumours that may otherwise remain undetectable. This technique enables surgeons to meticulously remove all cancerous tissue while preserving healthy surrounding tissue, thereby minimizing the risk of recurrence and promoting optimal patient outcomes.
Through Unfold AI’s integration with the Focal One robotic HIFU platform, urologists can deliver a bespoke, patient-tailored HIFU ablation procedure specifically designed for each individual’s prostate cancer treatment.
Wayne G. In collaboration with Avenda and FocalPoint, Dr. Brisbane, an assistant professor of urology at the David Geffen School of Medicine at the University of California, Los Angeles, played a key role in developing this innovative system. Dr. Brisbane’s insights offered a deeper understanding of how this expertise could potentially revolutionize urology practices.
Focal One’s advanced technology has the potential to revolutionize urology procedures by allowing surgeons to target specific areas of diseased tissue with precision and accuracy. This minimally invasive approach enables procedures to be performed more efficiently, reducing patient recovery time and minimizing scarring. By leveraging Focal One’s capabilities, urologists can treat conditions such as kidney stones, prostate cancer, and bladder tumors with unparalleled effectiveness and minimal risk of complications.
Wayne G. Brisbane, MD, an assistant professor of urology at the David Geffen School of Medicine at UCLA. | Supply: UCLA Well being
As a physician, the advent of Focal One has revolutionized my approach to treating patients diagnosed with localized prostate cancer. By allowing for precise identification and targeting of tumors while preserving surrounding tissue, this technology empowers me to tailor treatment plans to each individual’s unique needs and minimize potential complications.
The Focal One treatment enables targeted ablation of specific areas within the prostate, rather than treating the entire gland. While this novel approach may not yet have the same level of recognition, it has garnered widespread support from patients seeking to mitigate the undesirable consequences of treatment.
With Unfold AI’s cutting-edge 3D cancer-mapping capabilities, we accurately identify the optimal site for ablation. Conventional imaging modalities such as MRI may underestimate the extent of many types of cancer?
Unfolding AI converges disparate data points – magnetic resonance imaging, prostate-specific antigen levels, biopsy locations, and Gleason scores – into a comprehensive, three-dimensional framework, thereby enabling precise tumor ablation through informed surgical navigation.
What impact will this specialized knowledge have on patients’ results?
This expertise will significantly boost our ability to predict the extent of tumors, thereby enabling targeted therapy guided by advanced robotic systems. Eliminating uncertainty in cancer treatment.
Unfolding AI capabilities also enable clinicians to identify patients more accurately, particularly those situated between active surveillance and more intense treatment options, allowing for more targeted interventions.
The main dangers associated with HIFU procedures are rare but potentially severe complications such as bleeding, infection, and nerve damage. Additionally, patients may experience temporary or permanent loss of sensation in the treated area.
Focal One decreases these risks by utilizing advanced technology that precisely targets the treatment area, minimizing exposure to healthy tissue. Its unique focal zone allows for pinpoint accuracy, reducing the risk of collateral damage to surrounding tissues.
While HIFU remedies are generally considered non-invasive and safe, they still pose certain risks. These changes involve modifications to urinary and sexual function. While HIFU has shown promise in treating various cancers, a major consideration remains the risk of recurrent disease due to incomplete treatment.
By integrating Unfold AI with FocalOne, our goal is to mitigate the significant risk of incomplete ablations associated with HIFU technology.
Focal One streamlines my audio post-production process by seamlessly integrating with popular video editing software.
Focal One provides a seamless workflow and effortlessly integrates with Unfold AI.
The EDAP NRGx system, in collaboration with Unfold AI, is now poised to revolutionize the diagnosis and treatment of prostate disease with its advanced technology.
To what extent had you worked closely with Avenda Wellbeing leading up to this initial endeavour?
Prior to commencing the primary process, I collaborated closely with Avenda Health to gain a comprehensive grasp of the Focal One system’s features and functionalities. What distinguished our partnership was the in-depth exploration of therapy protocols, seamless integration of expertise, and learning how to harness the full potential of Unfold AI’s innovative 3D cancer mapping capabilities effectively?
Individuals struggling with these conditions have responded positively to the introduction of this innovative therapy.
Brisbane: Individuals affected by this condition have exhibited a favorable response to Focal One treatment. As a result, many people genuinely experience a sense of relief knowing that our targeted approach to eliminating the tumour is more precise, thereby significantly reducing the risk of inadvertently harming healthy tissue. Their admiration stems from the minimally invasive approach, which is a significant departure from traditional treatments that often raise concerns over potential adverse reactions.
Patients with cancer also benefit from the cutting-edge visualizations provided by Unfold AI’s three-dimensional tumour mapping technology. Studies suggest that some users experience a reduced incidence of adverse reactions when compared to traditional treatments, leading to a more favorable perception of the treatment approach. Their confidence has been significantly bolstered, leading to enhanced overall therapeutic experiences for patients.
The potential for applying these skills to a wide range of processes and operations seems promising.
I expect AI-generated maps to be utilized in conjunction with future robotic systems.
